Santhera Pharmaceuticals Holding AG (SANN) — Capital Reinvestment Ratio

Latest as of December 2023: 0.00x

Santhera Pharmaceuticals Holding AG (SANN) has a Capital Reinvestment Ratio of 0.00x as of December 2023, meaning it reinvests 0% of its operating cash flow (CHF62.63 Million) in capital expenditures (CHF90.00K). See Santhera Pharmaceuticals Holding AG (SANN) net asset quality to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

CHF62.63 Million
CHF

Capital Expenditures

CHF90.00K
CHF

Data as of

Dec 2023
Most recent filing

Santhera Pharmaceuticals Holding AG Capital Reinvestment Ratio (2019–2023)

This chart tracks Santhera Pharmaceuticals Holding AG's Capital Reinvestment Ratio across 2 annual periods. Check SANN total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Santhera Pharmaceuticals Holding AG (2019–2023)

Year-by-year Capital Reinvestment Ratio for Santhera Pharmaceuticals Holding AG from 2019 to 2023. For live market cap and broader valuation context, see Santhera Pharmaceuticals Holding AG market cap and net worth.

Year Reinvestment Ratio Operating CF (CHF) Capital Expenditures YoY Change
2023 0.50x CHF47.27 Million CHF23.74 Million ▲ +469.2%
2019 0.09x CHF2.60 Million CHF229.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow